Clinical OMICS

JAN-FEB 2018

Healthcare magazine for research scientists, labs, pathologists, hospitals, cancer centers, physicians and biopharma companies providing news articles, expert interviews and videos about molecular diagnostics in precision medicine

Issue link: https://clinicalomics.epubxp.com/i/926715

Contents of this Issue

Navigation

Page 33 of 51

Data & Informatics 32 Clinical OMICs January/February 2018 www.clinicalomics.com iSpecimen Data Connector Links Providers to Researchers iSpecimen recently launched a program designed to help healthcare providers offer their biospecimens to researchers more easily by seamlessly connecting their sample and data management sys- tems to the company's iSpecimen Market- place online platform. The iSpecimen Data Connector Program provides off-the-shelf data connectors for a variety of widely used medical record systems, including laboratory information management systems (LIMs), laboratory in- formation systems (LIs), and integrated elec- tronic medical record (EMR) systems. "Biorepositories and other healthcare organizations need more operating reve- nue, more awareness for their biospecimen collections, and an easy way to connect to researchers who desperately need samples," said Christopher Ianelli, M.D., Ph.D., found- er and CEO, iSpecimen. "Through our Data Connector Program and integration with the iSpecimen Marketplace, participating LIMS, LIS, and EMR vendors gain more value to offer their customers." The iSpecimen Data Connector Program is open to all major vendors of LIMs, LIs, EMR systems, and databases that manage bio- specimen data. Participating software ven- dors will receive up-front technology devel- opment support to interface their systems with the iSpecimen Marketplace, as well as marketing support designed to raise aware- ness of the combined solution, iSpecimen said. n Qiagen has rolled out an improved ver- sion of its Qiagen Clinical Insight (QCI) software that incorporates the AMP/ ASCO/CAP Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer. Qiagen said its QCI-Interpret bio- informatics solution is the first to include the guidelines, reflecting growing clinical implementation of next-generation sequencing (NGS) for genetic profiling of cancers. The AMP/ASCO/CAP guidelines are designed to establish a four-tiered system based on clinical evidence from drug labels, guidelines, and peer– reviewed publications for categoriz- ing the clinical significance of somatic sequence variants based on evidence of their impact on cancer care. The guidelines were published last January following their development by a multidisciplinary working group from the Association for Molecular Pathology (AMP) with participation by the American Society of Clinical Oncol- ogy (ASCO) and the College of Ameri- can Pathologists (CAP). The guidelines have been com- bined into Qiagen's Knowledge Base, a curated repository of medical and scientific literature, including updated information on approved drugs and clinical trials. Each piece of supporting clinical evidence is rated and linked to its source publication for further study. Laboratories may also change variant assessments based on their experience, tracking all changes in compliance with standard clinical procedures, Qia- gen said. "We have integrated the AMP/ ASCO/CAP guidelines with our deep Qiagen Knowledge Base to enable any molecular pathology lab to quickly and confidently report both the clini- cal relevance of somatic variants and the associated treatment options and clinical trials available to the oncolo- gist," Ramon Felciano, CTO and VP, strategy & technology, Qiagen Bioin- formatics, said in a statement. "QCI delivers the insights to advance preci- sion medicine." QCI-Interpret is cloud-based, enabling labs to immediately access clinical and scientific evidence that according to Qiagen is updated by its M.D. and Ph.D. staff. By detailing sup- porting evidence for potential treat- ments and clinical trials, QCI-Interpret offers clinical actionability and patho- genicity assessments with full trans- parency, Qiagen said. Qiagen announced the enhanced QCI software at the recent Association for Molecular Pathology (AMP) 2017 Annual Meeting in Salt Lake City. — Alex Philippidis Qiagen Integrates AMP/ ASCO/CAP Variant Guidelines into QCI-Interpret Solution Bogdanhoda / Getty Images 4X-image / Getty Images

Articles in this issue

Links on this page

Archives of this issue

view archives of Clinical OMICS - JAN-FEB 2018